New

Keep tabs on your favorite ETFs with a personalized weekly tracker. Create a Watchlist now →

Advertisement
ETF Central logo
Advertisement
HELX
Active ETF

Franklin Genomic Advancements ETF

This ETF provides exposure to Other Global Equities Read more

Active ETF
Last update 3/11/2026 at 1:30 PM
Live
Closed
This fund is part of
BioTech & Genomics
-0.26%
Last Price
$33.21
% Change
-0.35%
1W flows
-
1m flows
-
AuM
$22M
E/R
0.5%
Find out how industry players manage ETF portfolios.  Discover our library of Model portfolios
Advertisement
Compare HELX with
Another ETF ›

Trading data

Last sale
3/11/2026 at 1:30 PM
$33.21
Previous close
$33.33
Consolidated volume
03/10/2026
Join for free
Average volume
30 days
Join for free
Average discount or premium
30 days
Join for free
Average Bid/Ask spread
30 days
Join for free

HELX performance and flow charts

Performance

-6.0-5.0-4.0-3.0-2.0-1.00.01.0%Feb 10Feb 18Feb 25Mar 4

Flows

0

Get all the metrics on this page, and more, through a reliable ETF data feed

Daily, global ETF data for advanced analysis or integration into apps (API), from our partner Trackinsight.

Historic performance and flows

Data as of March 10, 2026
1M3MYTD1Y3Y5Y
Perf.-4.59%-9.58%-8.07%+19.05%+15.63%-19.83%
Flows-+$2M+$2M+$8M+$9M+$16M
Data as of March 10, 2026

Volatility and drawdown

3M1Y3Y5Y
Volatility+18.78%+23.05%+19.79%+23.96%
Max drawdown
-13.52%-16.74%-29.16%-58.50%
Max drawdown duration
62d141d458d1645d
Time to recover
N/A127d193dN/A

Exposure

Data as of January 31, 2026

Countries

USA
91.05%
Other
8.95%

Sectors

Health Care
85.71%
Other
14.29%

Diversification

Total weight of top 15 holdings out of 61

59.03%

Top 15 Holdings

GUARDANT HEALTH INC
7.23%
NATERA
7.04%
KRYSTAL BIOTECH INC
5.04%
MEDPACE HOLDINGS INC
4.62%
BRIDGEBIO PHARMA
3.95%
INSMED
3.87%
ADAPTIVE BIOTECHNOLOGIES
3.74%
SAMSUNG BIOLOGICS CO LTD
3.43%
UTD THERAPEUT
3.28%
ALNYLAM PHARMACEUTICALS
3.14%
LIGAND PHARMACEUTICALS
3.01%
VERTEX PHARMACEUTICALS
2.86%
US0463531089
2.8%
LILLY
2.51%
US88023B1035
2.49%

Characteristics

This fund is actively managed; it does not track an index.

This share class generates a stream of income by distributing dividends.

Management strategyActive
ProviderFranklin Templeton
N° of holdings61
Dividend policyDistributing
Trailing 12m distribution yield
Join for free
Inception dateFebruary 25, 2020
ESGNo

The ETF Institute® is now affiliated with ETF Central

The CETF certification is the only FINRA listed professional designation focused on ETFs.

Advertisement
Advertisement
Advertisement
Frequently asked questions about HELX

What type of ETF is HELX?

HELX is a Active ETF that provides exposure to Equity assets. It is managed by Franklin Templeton.

What does HELX invest in?

This ETF provides exposure to Other Global Equities. It is part of the segment: BioTech & Genomics.

What is the expense ratio of HELX?

The total expense ratio (TER) of HELX is 0.5%, representing the annual fee charged by the fund manager.

When was HELX launched?

HELX was launched on February 25, 2020, marking its entry into the ETF market.

Who is the issuer of HELX?

HELX is issued by Franklin Templeton.

What is the AUM of HELX?

As of March 10, 2026, HELX manages $21.68 M, reflecting the total assets held in the fund.

How has HELX performed recently?

As of March 10, 2026, HELX delivered a return of -4.59% over the past month (1M performance), -9.58% over the past three months (3M), and -8.07% year-to-date (YTD).

How many holdings are in HELX

As of January 31, 2026, HELX holds 61 securities in its portfolio. This level of diversification can influence the fund’s risk profile and exposure to individual assets.

How diversified is HELX?

As of January 31, 2026, HELX holds 61 securities, with 59.03% of its assets concentrated in its top 15 holdings.

What are the top holdings of HELX?

As of January 31, 2026, HELX holds a portfolio of 61 underlyings, with its largest positions including GUARDANT HEALTH INC, NATERA and KRYSTAL BIOTECH INC. These top holdings play a significant role in shaping the fund’s performance and exposure.

What countries or regions does HELX invest in?

As of January 31, 2026, HELX has its largest geographic exposures in USA.

What sectors or themes does HELX focus on?

As of January 31, 2026, HELX is primarily exposed to Health Care.

Advertisement
Advertisement
ETF U
Become a better investor with NYSE: The Home of ETFs
Visit the ETF U homepage
ETF Guides

Recent educational content

The ETF Show - US-Iran Conflict Sends Oil ETFs Soaring

Asset TV

The ETF Show - US-Iran Conflict Sends Oil ETFs Soaring

Lance McGray, Managing Director and Head of ETF Product at Advisors Asset Management joins The ETF Show.

Asset TV
By Asset TV · March 6, 2026
What's the Fund | Thrivent Small Cap Value ETF (Ticker: TSCV)

What’sTheFund

What's the Fund | Thrivent Small Cap Value ETF (Ticker: TSCV)

Kyle Detullio, ETF Capital Markets Specialist at Thrivent Asset Management, joins Ethan Hertzfeld on the NYSE trading floor to discuss the Thrivent Small Cap Value ETF (TSCV).

NYSE logo
By NYSE · March 6, 2026
What's the Fund | Thrivent Small-Mid Cap Equity ETF (Ticker: TSME)

What’sTheFund

What's the Fund | Thrivent Small-Mid Cap Equity ETF (Ticker: TSME)

Kyle Detullio, ETF Capital Markets Specialist at Thrivent Asset Management, joins Ethan Hertzfeld on the NYSE trading floor to discuss the Thrivent Small-Mid Cap Equity ETF (TSME).

NYSE logo
By NYSE · March 6, 2026
What's the Fund | Thrivent Mid Cap Value ETF (Ticker: TMVE)

What’sTheFund

What's the Fund | Thrivent Mid Cap Value ETF (Ticker: TMVE)

Kyle Detullio, ETF Capital Markets Specialist at Thrivent Asset Management, joins Ethan Hertzfeld on the NYSE trading floor to discuss the Thrivent Mid Cap Value ETF (TMVE).

NYSE logo
By NYSE · March 6, 2026

Browse all educational columns

Webcast on Demand

Calamos Investments Powers the Next Phase of the Autocallable Revolution

Join J.P. Morgan’s Bram Kaplan, Head of Americas Equity Derivatives Strategy and Matt Kaufman from Calamos Investments as they dive into the growing global opportunity in autocallable income—an increasingly dominant strategy within structured products, now available through ETFs.

Accepted for 1 CE Credit

Calamos Webcast
Sign up for our weekly newsletter
The latest news from The Home of ETFs, delivered straight to your inbox.